Patents by Inventor Daniela CIPOLLETTA

Daniela CIPOLLETTA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240228621
    Abstract: Embodiments provided herein, provide for variant IgG Fc polypeptides, dimeric molecules, pharmaceutical compositions, and methods that can be used to target at cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.
    Type: Application
    Filed: October 25, 2023
    Publication date: July 11, 2024
    Inventors: Yen-Lin Chen, Ryan Peckner, Nathan Higginson-Scott, Daniela Cipolletta, Yanfeng Zhou, Kevin Lewis Otipoby, Jyothsna Visweswaraiah
  • Patent number: 12030945
    Abstract: Embodiments provided herein, provide for variant IgG Fc polypeptides, dimeric molecules, pharmaceutical compositions, and methods that can be used to target at cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.
    Type: Grant
    Filed: October 25, 2023
    Date of Patent: July 9, 2024
    Assignee: Seismic Therapeutic, Inc.
    Inventors: Yen-Lin Chen, Ryan Peckner, Nathan Higginson-Scott, Daniela Cipolletta, Yanfeng Zhou, Kevin Lewis Otipoby, Jyothsna Visweswaraiah
  • Publication number: 20240132592
    Abstract: Embodiments provided herein, provide for variant IgG Fc polypeptides, dimeric molecules, pharmaceutical compositions, and methods that can be used to target at cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.
    Type: Application
    Filed: October 24, 2023
    Publication date: April 25, 2024
    Inventors: Yen-Lin Chen, Ryan Peckner, Nathan Higginson-Scott, Daniela Cipolletta, Yanfeng Zhou, Kevin Lewis Otipoby, Jyothsna Visweswaraiah
  • Patent number: 11001628
    Abstract: The present application n relates to a pharmaceutical composition comprising a PD-1 antibody and an M-CSF antibody. The combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: May 11, 2021
    Assignee: NOVARTIS AG
    Inventors: Marie-Louise Fjaellskog, John Scott Cameron, Zhu Cao, Daniela Cipolletta, Kenzie MacIsaac
  • Publication number: 20210015860
    Abstract: The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors; as well as pharmaceutical compositions that comprise such molecules and methods of use thereof.
    Type: Application
    Filed: April 9, 2020
    Publication date: January 21, 2021
    Inventors: Jennifer BROGDON, Daniela CIPOLLETTA, Glenn DRANOFF, Deborah A. KNEE, Fei WANG
  • Patent number: 10662247
    Abstract: The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors; as well as pharmaceutical compositions that comprise such molecules and methods of use thereof.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: May 26, 2020
    Assignee: Novartis AG
    Inventors: Jennifer Brogdon, Daniela Cipolletta, Glenn Dranoff, Deborah A. Knee, Fei Wang
  • Publication number: 20180222973
    Abstract: The present application n relates to a pharmaceutical composition comprising a PD-1 antibody and an M-CSF antibody. The combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer.
    Type: Application
    Filed: July 27, 2016
    Publication date: August 9, 2018
    Inventors: Marie-Louise Fjaellskog, John Scott Cameron, Zhu Cao, Daniela Cipolletta, kenzie Maclsaac
  • Publication number: 20170306037
    Abstract: The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors; as well as pharmaceutical compositions that comprise such molecules and methods of use thereof.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 26, 2017
    Inventors: Jennifer BROGDON, Daniela CIPOLLETTA, Glenn DRANOFF, Deborah A. KNEE, Fei WANG
  • Publication number: 20170306038
    Abstract: The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18), and compositions comprising one or more additional therapeutic agents. Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers. Also provided are methods of use of combinations that find use in treatment or prevention of cancerous or infectious conditions and disorders.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 26, 2017
    Inventors: Jennifer BROGDON, Daniela CIPOLLETTA, Glenn DRANOFF, Deborah A. KNEE, Fei WANG